Abstract | INTRODUCTION: METHODS: The database for the analyses comprised 22 studies including 16 open-label and six placebo-controlled studies. Based on the quality, sample size, and study design of studies prior to 2000, the database was then restricted to articles published after the year 2000. Effect sizes were calculated for each reported measure within a study to calculate an average effect size per study. RESULTS: The mean effect size for the database was 1.047 and the sample weighted mean effect size was 1.108, with a variance of 0.18. CONCLUSIONS: Outcome measures demonstrated mean improvement in problematic behaviors equaling one standard deviation, and thus current evidence supports the effectiveness of risperidone in managing behavioral problems and symptoms for children with ASD. Although Risperdal has several adverse effects, most are manageable or extremely rare. An exception is rapid weight gain, which is common and can create significant health problems. Overall, for most children with autism and irritable and aggressive behavior, risperidone is an effective psychopharmacological treatment.
|
Authors | Akanksha Sharma, Steven R Shaw |
Journal | Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners
(J Pediatr Health Care)
2012 Jul-Aug
Vol. 26
Issue 4
Pg. 291-9
ISSN: 1532-656X [Electronic] United States |
PMID | 22726714
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | Copyright © 2012 National Association of Pediatric Nurse Practitioners. Published by Mosby, Inc. All rights reserved. |
Chemical References |
- Antipsychotic Agents
- Risperidone
|
Topics |
- Adolescent
- Antipsychotic Agents
(administration & dosage, adverse effects)
- Child
- Child Behavior Disorders
(drug therapy, psychology)
- Child Development Disorders, Pervasive
(drug therapy, psychology)
- Child, Preschool
- Evidence-Based Medicine
- Female
- Humans
- Male
- Risperidone
(administration & dosage, adverse effects)
- Treatment Outcome
|